BONE MARROW SITES DIFFERENTLY IMPRINT DORMANCY AND CHEMORESISTANCE TO T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Françoise Pflumio, 183931
ARNT/HIF-1BETA LINKS POOR CLINICAL OUTCOME TO MICROENVIRONMENTAL HYPOXIA AND HIGH-RISK 1Q GAIN IN MULTIPLE MYELOMA
EHA Learning Center, Fengyan Jin, 183932
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
EHA Learning Center, Gilles Salles, 183934
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
EHA Learning Center, Paul Hamlin, 182060
13-YR FOLLOW UP OF MULTICENTER RANDOMIZED CHOP-R VS R-HDS TRIAL IN HIGH RISK FOLLICULAR LYMPHOMA PATIENTS: PROLONGED SURVIVAL AND HIGH RATE OF LONG-TERM DISEASE FREE SURVIVORS
EHA Learning Center, Corrado Tarella, 182065
PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY
EHA Learning Center, Paula Rodriguez-Otero, 182070
POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201 + A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COMPARED WITH HISTORICAL CONTROLS
EHA Learning Center, Andreas Reiter, 182075
A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Moshe Y. Levy, 182080
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH DELETION 5Q OR MONOSOMY 5: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT
EHA Learning Center, Xavier Poiré, 182085
T-CELL RECEPTOR Β (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATUMOMAB TREATMENT.
EHA Learning Center, Henrik Knecht, 182090
EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Stephan Grupp, 182095
DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES
EHA Learning Center, Francesca Vinchi, 182100
CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE
EHA Learning Center, Tobias Haas, 182105
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
EHA Learning Center, Loretta Nastoupil, 182059
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA
EHA Learning Center, Pier Luigi Zinzani, 182064
COMPARISON OF DENOSUMAB (DMB) WITH ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE DISEASE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; AN INTERNATIONAL, RANDOMIZED, DOUBLE BLIND TRIAL
EHA Learning Center, Evangelos Terpos, 182069
MOLECULAR RESPONSE TO HYDROXYUREA AND ROPEGINTERFERON ALFA-2B IN THE PROUD-PV RANDOMIZED PHASE 3 TRIAL
EHA Learning Center, Jean-Jacques Kiladjian, 182074
SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT
EHA Learning Center, Betül Oran, 182079
CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Sebastian Giebel, 182084
POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14,ISRCTN 66541317)
EHA Learning Center, Dina Okasha, 182089
LETERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
EHA Learning Center, Rafael Duarte, 182094
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
EHA Learning Center, Aaron Weigl, 182099
MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES
EHA Learning Center, Antonio Galleu, 182104
VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL
EHA Learning Center, Stephan Stilgenbauer, 182058
EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY
EHA Learning Center, Pier Luigi Zinzani, 182063
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
EHA Learning Center, Charlotte Pawlyn, 182068
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
EHA Learning Center, C Harrison, 182073
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY
EHA Learning Center, Charles Craddock, 182078
IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, Livia Giannoni, 182083
MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM
EHA Learning Center, Monika Brüggemann, 182088
INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM
EHA Learning Center, Alessandra Forcina, 182093
UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT
EHA Learning Center, Gianluca De Rosa, 182098
GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES
EHA Learning Center, Laura Escribà, 182103
THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY
EHA Learning Center, Peter Hillmen, 182057
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
EHA Learning Center, Wolfgang Hiddemann, 182062
TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)
EHA Learning Center, Paul Richardson, 182067
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
EHA Learning Center, Jason R. Gotlib, 182072
FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70
EHA Learning Center, Ana Garrido, 182077
GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Zinaida Peric, 182082
PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Anna Lucia Fedullo, 182087
CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAA RANDOMIZED STUDY BY THE SWEDISH CLL GROUP
EHA Learning Center, Tobias Svensson, 182092
IDENTIFICATION OF GUANOSINE 5ʹ-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY
EHA Learning Center, Stanzin angmo, 182097
CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY
EHA Learning Center, Nicholas HUNTINGTON, 182102
IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP
EHA Learning Center, Carolina Moreno Atanasio, 182056
COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY
EHA Learning Center, Judith Trotman, 182061
PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
EHA Learning Center, Irene Ghobrial, 182066
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
EHA Learning Center, Martin Greisshammer, 182071
LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY
EHA Learning Center, Marius Flasinski, 182076
21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)
EHA Learning Center, Karl Staser, 182081
IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Masafumi Seki, 182086
DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)
EHA Learning Center, Ildefonso Espigado, 182091
LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.
EHA Learning Center, Sandro Altamura, 182096
A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL
EHA Learning Center, Mark Walters, 182101
BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES
EHA Learning Center, Fanni Rencz, 182017
AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION - IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.
EHA Learning Center, Dunnya DE-SILVA, 182018
COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Matthew Matthew Seftel, 182019
THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?
EHA Learning Center, Rocio Parody Porras, 182033
FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.
EHA Learning Center, María Dolores Caballero, 182034
EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS
EHA Learning Center, Paul Richardson, 182035
INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?
EHA Learning Center, Anmol Baranwal, 182050
GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.
EHA Learning Center, Angel F Remacha, 182052
SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL
EHA Learning Center, Marina Kunstreich, 181802
FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS
EHA Learning Center, Dr. Fabian Lang, 181803
ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
EHA Learning Center, Shannon Maude, 181804
PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS
EHA Learning Center, Pedro Casado-Izquierdo, 181819
CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Frauke Theis, 181820
GFI1B - A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS
EHA Learning Center, Aniththa Thivakaran, 181821
FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES
EHA Learning Center, Claudia Haferlach, 181836
COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
EHA Learning Center, Kiyomi Morita, 181837
THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY
EHA Learning Center, Daehun kwak, 181838
WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA
EHA Learning Center, Katja De Paepe, 181852
PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.
EHA Learning Center, Joost Vermaat, 181854
HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY
EHA Learning Center, Marcus Hentrich, 181855
NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
EHA Learning Center, Federico Pozzo, 181870
CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.
EHA Learning Center, Julia Almeida, 181871
NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES
EHA Learning Center, Andrejs Braun, 181872
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, sara galimberti, 181886
ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS
EHA Learning Center, Manuela Mancini, 181887
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
EHA Learning Center, David Ross, 181888
IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Del Mar MAÑU PEREIRA, 181902
CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME
EHA Learning Center, Bruno Fattizzo, 181903
HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE
EHA Learning Center, Sihem Sadoudi, 181904
ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)
EHA Learning Center, Andres Forero-Torres, 181920
PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
EHA Learning Center, John Burke, 181921
A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA
EHA Learning Center, Michinori Ogura, 181922
PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).
EHA Learning Center, Philippe Rodon, 181936
TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Paul Richardson, 181937
ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS
EHA Learning Center, Astrid Hasibeder, 181938
IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Ana Alfonso Pierola, 181952
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
EHA Learning Center, Aristoteles Giagounidis, 181953
RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)
EHA Learning Center, Marino Clavio, 181954
PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
EHA Learning Center, Estefania Garcia-Guerrero, 181968
BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jeremy Ross, 181969
THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY
EHA Learning Center, Berdien Oortgiesen, 181970
METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE
EHA Learning Center, Suzanne McPherson, 181984
ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION
EHA Learning Center, Tata Nageswara Rao, 181985
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Moshe Talpaz, 181986
CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.
EHA Learning Center, Alberto Orfao, 182000
MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY
EHA Learning Center, Laura vinas, 182001
PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS
EHA Learning Center, Giulia Geranio, 182002